Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 3 3Phase 1/2 2

Status

Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Lymphoma 27Lymphoma, Non-Hodgkin 24Leukemia, Lymphocytic, Chronic, B-Cell 24Lymphoma, Mantle-Cell 23Lymphoma, Follicular 17Lymphoma, Large B-Cell, Diffuse 15Multiple Myeloma 14Recurrence 13Hodgkin Disease 12Lymphoma, B-Cell, Marginal Zone 7Leukemia 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms, Plasma Cell 4Neoplasms 4Leukemia, B-Cell 4Hematologic Neoplasms 4Myeloproliferative Disorders 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphoid 3Small Cell Lung Carcinoma 2Leukemia, Biphenotypic, Acute 2Burkitt Lymphoma 2Sezary Syndrome 1Sarcoma 1Renal Insufficiency, Chronic 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Bendamustine Hydrochloride × Clear all
NCT03755804 2026-04-23

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
232 enrolled
Lymphoid

Hodgkin Disease, Neoplasms

NCT04510636 2024-03-22

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

University Health Network, Toronto

Phase 2 Recruiting
37 enrolled

Neoplasms, Recurrence

NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Sheba Medical Center

Phase 2 Unknown
72 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Novartis

Phase 2 Completed
99 enrolled 27 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡